Literature DB >> 18688236

Off-label or off-limits?

Mark Ratner1, Trisha Gura.   

Abstract

Mesh:

Year:  2008        PMID: 18688236     DOI: 10.1038/nbt0808-867

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

Review 1.  New challenges to medicare beneficiary access to mAbs.

Authors:  Joshua Cohen; Andrew Wilson
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

2.  Pfizer settles largest ever fraud suit for off-label promotion.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2009-11       Impact factor: 54.908

3.  Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.

Authors:  Martina Bonifazi; Marta Rossi; Lorenzo Moja; Vincenzo Davide Scigliano; Matteo Franchi; Carlo La Vecchia; Carlo Zocchetti; Eva Negri
Journal:  Oncologist       Date:  2011-12-30

4.  Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.

Authors:  Kristen Underhill
Journal:  Am J Law Med       Date:  2012

5.  Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular Leakage.

Authors:  Da-Eun Hwang; Jeong-Hyun Ryou; Jong Rok Oh; Jung Woo Han; Tae Kwann Park; Hak-Sung Kim
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

6.  Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.

Authors:  S Swaroop Vedula; Palko S Goldman; Ilyas J Rona; Thomas M Greene; Kay Dickersin
Journal:  Trials       Date:  2012-08-13       Impact factor: 2.279

7.  Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.

Authors:  Andreas Vilhelmsson; Courtney Davis; Shai Mulinari
Journal:  PLoS Med       Date:  2016-01-26       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.